Vor Biopharma Inc. · NASDAQ:VOR
Vor Biopharma — Investor Presentation (September 2026)
60 slides from Vor Biopharma's investor presentation, September 2026
Slide 1: Global Science. One Purpose. Corporate Presentation
Global Science. One Purpose. Corporate Presentation September 2026
Slide 2: Forward Looking Statement
Forward Looking Statement This presentation (the “Presentation”) contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 about Vor Biopharma Inc. (“Vor,” “Vor Bio” or the “Company”). The words “aim,” “anticipate,” “believe,” “can,” “could,” “des
Slide 3: Immune Remodulation Through BAFF/APRIL Inhibition
Immune Remodulation Through BAFF/APRIL Inhibition OUR AMBITION To Transform the Approach to B Cell-Driven Autoimmune Disease Selective BAFF/APRIL inhibitor designed to reduce pathogenic B cells and antibodies while preserving immune protection TELITACICEPT Clinically validated in 8+ autoimmune indic
Slide 4: Dual BAFF/APRIL Inhibition Targets Autoreactive B Cells and Plasma Cells
Dual BAFF/APRIL Inhibition Targets Autoreactive B Cells and Plasma Cells Disease modification through upstream control of B cell survival and downstream antibody production Telitacicept TACI-Fc fusion protein: dual inhibition of BAFF/APRIL Blocking BAFF inhibits abnormal Blocking APRIL inhibits abno
Slide 5: Telitacicept Preferentially Depletes Pathogenic Cells While Preserving Humoral Immunity
TELITACICEPT PREFERENTIALLY DEPLETES PATHOGENIC CELLS WHILE PRESERVING HUMORAL IMMUNITY SYSTEMIC LUPUS MYASTHENIA MYASTHENIA ERYTHEMATOSUS (SLE) GRAVIS (MG) GRAVIS (MG) (n= 20 | 24 Weeks)1 (n= 22 | 24 Weeks)2 (n= 35 | 24 Weeks)3 Pathogenic autoantibodies fell ~1.6-2.4x more than Anti-dsDNA Total IgG
Slide 6: Established Efficacy in China Across Autoimmune Diseases
Established Efficacy in China Across Autoimmune Diseases 5 Commercial Approvals Validated Commercial Therapy in China Across Diverse Autoimmune Diseases 3 Best-In-Disease Unique Dual BAFF/APRIL Inhibition Drives Superior Clinical Benefit 2021 - Systemic Lupus Erythematosus (SLE)† Systemic Lupus Eryt
Slide 7: Favorable Safety At Scale
Favorable Safety 10s of Patients Treated At Scale Thousands Commercially in China Favorable and Predictable Safety Profile Observed Frequency (%) of safety events reported in clinical trials Among ~2,400* Patients Studied in Clinical Trials Telitacicept Placebo (n=1669) (n=711) No Burdensome Upper r
Slide 8: Advancing the Leading BAFF/APRIL Inhibitor
Advancing the Leading BAFF/APRIL Inhibitor Strong cash position of ~$515M* with runway into early 2029 expected to cover key milestones Vor Indications Preclinical Phase 1 Phase 2 Phase 3 Marketing Approval Milestones Generalized Myasthenia Gravis (gMG) Phase 3 Global Phase 3 Topline Data (1H27) Ocu
Slide 9: Myasthenia Gravis
Myasthenia Gravis Moving Beyond Complement and IgG Therapies 9
Slide 10: A Large and Growing Global Opportunity in Myasthenia Gravis
A Large and Growing Global Opportunity in Myasthenia Gravis ~260,000 diagnosed MG patients across key markets1 Significant Burden • A large, diagnosed patient population across key markets establishes a substantial initial opportunity ~140k EU prevalence Favorable Growth Drivers ~220k China prevalen
Slide 11: MG Market Rapidly Expanding But Lacks Disease-Modifying Treatments
MG Market Rapidly Expanding But Lacks Disease-Modifying Treatments High growth market with underserved patient segments ~$11B 1 Projected Market Size (2032) gMG US Biologic Sales ~90,000 Diagnosed MG patients in the US 57% ~$4.8B 1 CAGR increase since 2018 60% Potential expansion of branded medicine
Slide 12: Current Myasthenia Gravis Therapies Target Symptoms, Not Disease
Current Myasthenia Gravis Therapies Target Symptoms, Not Disease Even with the availability of biologics, unmet need for new therapies remain AChR+ MG MuSK+ MG Biologic use rising (~35% of gMG patients1) with choices driven by efficacy, convenience, phenotype, and coverage AChEi Steroids ± RTX FcRn
Slide 13: The Need for Therapies to Go Beyond IgG in Myasthenia Gravis
The Need for Therapies to Go Beyond IgG in Myasthenia Gravis New evidence shows IgA and IgM drive pathology, demanding broader therapeutic strategies Distribution of AChR Autoantibody Isotypes and IgG Subclasses in MG Patients carry different blends of IgG, IgA, and IgM, driving overlapping mechanis
Slide 14: Myasthenia Gravis: The Beachhead Indication
Myasthenia Gravis: The Beachhead Indication Telitacicept demonstrated depth, durability, and a differentiated upstream mechanism P LACE BO- ADJ US TE D MG -ADL CHANG E FRO M BAS E LI NE AT W E E K 2 4 Across leading mechanisms, telitacicept 0 demonstrates largest placebo-adjusted Telitacicept PBO-ad
Slide 15: Durability in Myasthenia Gravis | Upstream vs Downstream Agents
Durability in Myasthenia Gravis | Upstream vs Downstream Agents How a therapy acts on antibody production and clearance yields different durability profiles UPSTREAM DOWNSTREAM AMGEN PHASE 3 MINT TRIAL ARGENX PHASE 3B ADAPT NXT TRIAL UPLIZNA | Least Square Mean Change From Baseline in MG-ADL Score,
Slide 16: Even At MG-ADL Parity, Telitacicept Still Competes
Even At MG-ADL Parity, Telitacicept Still Competes Physician research suggests a meaningful commercial floor for telitacicept at a parity MG-ADL, while UPLIZNA uptake validates B-cell demand in real time 9.4% EXPECTED UPLIZNA GMG 69% PREFERRED BAFF/APRIL 21% PHYSICIAN-ALLOCATED BIOLOGIC- SHARE BY 1Q
Slide 17: Phase 3 Trial in Generalized Myasthenia Gravis Completed in China
Phase 3 Trial in Generalized Myasthenia Gravis Completed in China Best-in-disease profile in China; randomized, double-blind, placebo-controlled study Double-Blind Treatment Period Open-Label Extension Period (24 Weeks) (24 Weeks) Primary Endpoint • Change from baseline in MG-ADL at 24 weeks 114 Adu
Slide 18: Well Balanced Baseline Characteristics
Well Balanced Baseline Characteristics Consistent with recent global Phase 3 populations Telitacicept Placebo Screening (n=148) (N=57) (N=57) Age (yr), mean ± SD 49.1 ± 14.69 49.6 ± 15.03 Sex Randomized (n=114) Male, n (%) 30 (52.6) 21 (36.8) Female, n (%) 27 (47.4) 36 (63.2) Received Double-Blind T
Slide 19: Telitacicept Shows Potential Best-In-Disease Profile in gMG (MG-ADL)
Telitacicept Shows Potential Best-In-Disease Profile in gMG Telitacicept delivered 4.8-point MG-ADL separation from placebo, the largest reported in gMG Change in MG-ADL Score from Baseline Based on historical clinical data; not a head-to-head trial N=57 | Wk 24 N=84 | Wk 26 N=67 | Day 43 N=77 | Wk
Slide 20: Telitacicept Shows Potential Best-In-Disease Profile in gMG (QMG)
Telitacicept Shows Potential Best-In-Disease Profile in gMG Telitacicept delivered 6.4-point QMG separation from placebo, the largest reported in gMG Change in QMG Score from Baseline Based on historical clinical data; not a head-to-head trial N=57 | Wk 24 N=84 | Wk 26 N=67 | Day 43 N=77 | Wk 24 N=6
Slide 21: Telitacicept Demonstrated Durable MG-ADL Over Time
Telitacicept Demonstrated Durable MG-ADL Over Time Sustained and deepening functional improvement through 48 weeks P E RCE NTAG E O F PATI E NTS ACHI E V I NG I MP RO V E ME NT ME AN CHANG E I N MG -ADL S CO RE I N MG -ADL BY S CO RE THRE S HO LD AT W E E K 4 8 1 OLE Period 0 Patients in placebo gro
Slide 22: OLE Data Highlight the Significant Change in MG-ADL Scores
OLE Data Highlight the Significant Change in MG-ADL Scores Seen With Telitacicept vs Placebo Mean Change in MG-ADL Score Percentage of Patients With ≥3-Point Reduction in MG-ADL Score from Baseline 1 Mean change from baseline (95% CI) OLE Period 100 0 Patients in placebo group 96.2 switched to telit
Slide 23: OLE Data Highlight the Significant Change in QMG Scores
OLE Data Highlight the Significant Change in QMG Scores Seen With Telitacicept vs Placebo Percentage of Patients With ≥5-Point Reduction Mean Change in QMG Score in QMG Score from Baseline 0 100 Mean change from baseline (95% CI) OLE Period 94.2 -1 Patients in placebo group 90.2 87 -2 switched to te
Slide 24: Consistent Reduction in IgG, IgA, IgM, and B Cells
Consistent Reduction in IgG, IgA, IgM, and B Cells IgG IgA 40 40 Percentage change from baseline, Percentage change from baseline, 20 20 0 0 mean ±SD mean ±SD -20 -20 -30.72% -40 -40 -35.81% -60 -60 -58.10% -80 -80 -60.60% -100 -100 0 4 8 12 16 20 24 28 32 36 40 44 48 0 4 8 12 16 20 24 28 32 36 40 4
Slide 25: Favorable Safety Profile in gMG
Favorable Safety Profile in gMG Consistent with data from clinical trials in SLE, RA, SjD, and IgAN, and post-marketing data Randomized Control Period (Baseline to Week 24)1 OLE Period (Weeks 24-48)2 Placebo → Telitacicept Placebo Telitacicept 240 mg Telitacicept 240 mg (n=57) (n=57) (n=54) (n=53) n
Slide 26: Telitacicept Delivers Lasting Disease Control vs. Cyclic Relapse from FcRn Inhibitors
Telitacicept Delivers Lasting Disease Control vs. Cyclic Relapse from FcRn Inhibitors REMEGEN PHASE 3 CHINA TRIAL ARGENX PHASE 3 ADAPT TRIAL Mean Change in MG-ADL Score† Mean Change in Total MG-ADL From Cycle 1 Baseline Over Time in AChR-Ab Positive Patients (mITT Analysis Set) 0 -1 -0.91 LEAST SQUA
Slide 27: BAFF/APRIL Inhibition Creates the Potential for a Better Clinical Profile
BAFF/APRIL Inhibition Creates the Potential for a Better Clinical Profile Telitacicept avoiding extreme IgG lowering and B cell depletion supporting depth, breadth and durability Telitacicept MoA TACI-Fc Anti-FcRn Anti-CD19 IgG Reduction 25-35% 60-65% ~9%a AutoAb Reduction ~65%† ~57%‡ ~10%* Selectiv
Slide 28: gMG Has Approved Therapies. Predictability Is Still An Issue.
gMG Has 7 Approved Therapies. * Predictability Is Still An Issue. China Phase 3 data suggest telitacicept may offer broad, deep, and durable responses that could support more consistent disease control BREADTH DEPTH DURABILITY ~94% 1in2 1in5 Patients with baseline Patients with baseline ~83% Remaini
Slide 29: UPSTREAM MG: Global Phase 3 in Generalized Myasthenia Gravis
UPSTREAM MG: Global Phase 3 in Generalized Myasthenia Gravis Potential best- and first-in-class BAFF/APRIL inhibitor; randomized, double-blind, placebo-controlled study Double Blind Treatment Period Open-Label Extension Period (24 Weeks) (48 Weeks) Primary Endpoint • Change from baseline in MG-relat
Slide 30: Sjögren's Disease
Sjögren's Disease Moving Beyond Symptom Management 30
Slide 31: Sjögren's: A Large, Vastly Underserved Autoimmune Disease
Sjögren’s: A Large, Vastly Underserved Autoimmune Disease Targeting ~100,0001 addressable patient US opportunity with a potential best-in-disease profile ESSDAI 0 Fatigue, difficulty concentrating Symptom-Directed Dry eyes 1 Local/topical therapies for dryness Difficult swallowing, dry mouth, swolle
Slide 32: Sjögren's: One of the Most Common Systemic Autoimmune Diseases Globally
Sjögren’s: One of the Most Common Systemic Autoimmune Diseases Globally ~870,000 diagnosed Sjögren’s patients across key markets1 Favorable Growth Drivers • Rising diagnosis rates from better awareness and testing Underpenetrated Market • No approved disease-modifying systemic ~450k EU prevalence ~1
Slide 33: Sjögren's Disease: The White Space Expansion Opportunity
Sjögren’s Disease: The White Space Expansion Opportunity Telitacicept demonstrated depth, durability, and a differentiated upstream mechanism P LACE BO - ADJ US TE D E S S DAI CHANGE FROM BAS E LI NE AT W E E K 2 4 Across leading mechanisms, telitacicept P H AS E 3 T R I AL S demonstrates largest pl
Slide 34: Durability in Sjögren's Disease | Upstream vs Downstream Agents
Durability in Sjögren’s Disease | Upstream vs Downstream Agents How a therapy acts on antibody production and clearance yields different durability profiles UPSTREAM DOWNSTREAM NOVARTIS PHASE 3 NEPTUNUS TRIAL ARGENX PHASE 2 RHO+ OPEN -LABEL EXTENSION TRIAL Ianalumab | Mean Change from Baseline ESSDA
Slide 35: Phase 3 Trial in Primary Sjögren's Disease Completed in China
Phase 3 Trial in Primary Sjögren's Disease Completed in China Best-in-disease profile in China; randomized, double-blind, placebo-controlled study Double-Blind Treatment Period Double-Blind Treatment Period (24 Weeks) (24 Weeks) Primary Endpoint • Change from baseline in ESSDAI at 24 weeks Telitacic
Slide 36: Patient Disposition
Patient Disposition Strong study execution across 79 sites in China Screening (n=480) Randomized (n=381) Received Treatment in Stage A (n=380) Placebo* Telitacicept 80mg Telitacicept 160mg (n=127) (n=126) (n=127) Treatment Discontinuation (n=21) Treatment Discontinuation (n=22) Treatment Discontinua
Slide 37: Baseline Characteristics
Baseline Characteristics Well-balanced, representative patient population across treatment arms Telitacicept 160mg Telitacicept 80mg Placebo Total (n=127) (n=127) (n=127) (n=381) Age (yr), Mean (SD) 45.9 (12.29) 44.6 (12.06) 47.3 (12.75) 46.0 (12.39) Body Weight (kg), Mean (SD) 55.89 (9.04) 56.88 (8
Slide 38: Telitacicept Shows Potential Best-In-Disease Profile in pSjD (ESSDAI)
Telitacicept Shows Potential Best-In-Disease Profile in pSjD Telitacicept delivered 3.8-point ESSDAI separation from placebo, the largest reported in SjD Change in ESSDAI Score from Baseline Based on historical clinical data; not a head-to-head trial P H AS E 3 T R I AL S P H AS E 2 T R I AL S NEPTU
Slide 39: Telitacicept Shows Potential Best-In-Disease Profile in pSjD (ESSPRI)
Telitacicept Shows Potential Best-In-Disease Profile in pSjD Telitacicept delivered 1.5-point ESSPRI separation from placebo, the largest reported in SjD Change in ESSPRI Score from Baseline Based on historical clinical data; not a head-to-head trial P H AS E 3 T R I AL S P H AS E 2 T R I AL S NEPTU
Slide 40: Deep, Consistent ESSDAI Reduction Through 48 Weeks
Deep, Consistent ESSDAI Reduction Through 48 Weeks 7x greater improvement means fewer active symptoms and broader systemic relief for patients CHANG E FRO M BAS E LI NE (P O I NT) I N E S S DAI CHANG E FRO M BAS E LI NE (P O I NT) I N E S S DAI S CORE OV E R W E E KS 0 -2 4 ⁜ S CORE OV E R W E E KS
Slide 41: Deep, Consistent ClinESSDAI Reduction Through 48 Weeks
Deep, Consistent ClinESSDAI Reduction Through 48 Weeks Sustained improvement in clinical benefit beyond serologic change CHANG E FRO M BAS E LI NE (P O I NT) I N CL I NE S S DAI S CO RE O V E R W E E KS 0-4 8 ⁜ ⁑ 160mg 80mg Placebo ESSDAI and ClinESSDAI remain nearly identical at week 48 CHANGE FROM
Slide 42: Sustained Improvement in ESSPRI Through 48 Weeks
Sustained Improvement in ESSPRI Through 48 Weeks Reduction in patient-reported fatigue, pain, and dryness by ~2.6 points at one year CHANG E FRO M BAS E LI NE (P O I NT) I N E S S P RI CHANG E FRO M BAS E LI NE (P O I NT) I N E S S P RI S CORE OV E R W E E KS 0 -2 4 ⁜ S CORE OV E R W E E KS 0 -4 8 ⁑
Slide 43: Early, Broad Symptom Improvements Observed with Telitacicept
Early, Broad Symptom Improvements Observed with Telitacicept Nearly 90% of patients report improvement as physicians confirm disease control in 3 out of 4 patients P RO P O RTI O N O F PARTI CI PANTS W I TH ≥3 -P O I NT P RO P O RTI O N O F PARTI CI PANTS W I TH ≥ 1 -P O I NT O R RE DUCTI O N FRO M
Slide 44: More Than Half of Patients Achieve Low Disease Activity
More Than Half of Patients Achieve Low Disease Activity Nearly 5x more patients on 160mg vs placebo achieved this threshold P RO P O RT I O N O F PART I CI PANT S W I T H E S S DAI S CO RE <5 P O I NTS O V E R TI ME ⁜ ⁑ 160mg 80mg Placebo Low Disease Activity (ESSDAI <5) 100% Represents Minimal Syst
Slide 45: BAFF/APRIL MOA Yields Improvement Across Key ESSDAI Domains
BAFF/APRIL MOA Yields Improvement Across Key ESSDAI Domains Lack of domain worsening supports balanced B cell modulation without over-suppression CHANGE FROM BASELINE IN ESSDAI SCORE BY DOMAIN AT 24 WEEKS 0.4 0.3 0.2 0.1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 -0.2 -0.1 -0.1 -0.1 -0.1 -0.1 -0.1-0.1 -0.1 -0.4
Slide 46: BAFF/APRIL MOA Associated With Improvement Across All ESSPRI Domains
BAFF/APRIL MOA Associated With Improvement Across All ESSPRI Domains Meaningful improvement across dryness, fatigue, and pain – symptoms that define daily patient life CHANGE FROM BASELINE IN ESSPRI SCORE BY DOMAIN AT 24 WEEKS 0 0 -0.2 -0.5 -0.6 -1 -1 -1 -1.1 -1.5 -1.4 -2 -1.8 -2.2 -2.5 Dryness Fati
Slide 47: STAR: Exploratory Endpoint Demonstrates Multi-Domain Improvement
STAR: Exploratory Endpoint Demonstrates Multi-Domain Improvement Nearly 3 in 4 patients achieved ≥5 point response STAR Responders (%) at Week 24 Telitacicept 160mg 74.8% Telitacicept 80mg 53.2% • STAR integrates systemic disease activity (ClinESSDAI), symptoms Placebo (ESSPRI), and glandular functi
Slide 48: CRESS: Exploratory Endpoint Demonstrates Broad, Balanced Efficacy
CRESS: Exploratory Endpoint Demonstrates Broad, Balanced Efficacy Nearly 7 in 10 patients achieved ≥3 point response CRESS Responders (%) at Week 24 Telitacicept 160mg 69.6% Telitacicept 80mg 50.4% Placebo • Response in the systemic disease activity domain is defined as low disease activity at follo
Slide 49: Consistent Reduction in IgG, IgA, IgM, and B Cells
Consistent Reduction in IgG, IgA, IgM, and B Cells IGG IGA 160mg 80mg Placebo 160mg 80mg Placebo 10% # # # # # # # # # # # # IGA CHANGE FROM BASELINE (%) IGG CHANGE FROM BASELINE (%) # # # # # # # # # # # # # # # # # # # # # # # # 10% ǂ # # # # # # # # # # # 0% -0.18% 2.08% (FAS, MEAN±SE ) (FAS, MEA
Slide 50: Favorable Safety Profile in pSjD
Favorable Safety Profile in pSjD Consistent with data from clinical trials in SLE, RA, gMG, and IgAN, and post-marketing data Telitacicept 160mg Telitacicept 80 mg Placebo Group (N=127) (N=126) (N=127) TEAE, n(%) 122 (96.1) 119 (94.4) 112 (88.2) TRAE, n(%) 107 (84.3) 106 (84.1) 74 (58.3) TESAE, n(%)
Slide 51: UPSTREAM SjD: Global Phase 3 Trial in Primary Sjögren's Disease
UPSTREAM SjD: Global Phase 3 Trial in Primary Sjögren's Disease Potential best- and first-in-class BAFF/APRIL inhibitor; randomized, double-blind, placebo-controlled study Double Blind Treatment Period Follow-Up Period (48 Weeks) (8 Weeks) Primary Endpoint • Change from baseline in ESSDAI at 48 week
Slide 52: Global Precedents for China-to-Global Translatability
Global Precedents for China-to-Global Translatability Moving Beyond Geographic Boundaries 52
Slide 53: MG: Batoclimab Shows Consistent MG-ADL Improvement Independent of Region
MG: Batoclimab Shows Consistent MG-ADL Improvement Independent of Region PBO-adjusted MG-ADL Δ: −1.9 China vs −2.0 Global China Global Metric n=131 | 6 weeks n=164 | 12 weeks What It Means (JAMA Neurol 2024) (Immunovant 2025) Baseline MG-ADL 8.4 (8.5) 8.8 (8.7) Similar disease severity (PBO) PBO MG-
Slide 54: MG: Nipocalimab Shows Consistent MG-ADL Improvement Independent of Region
MG: Nipocalimab Shows Consistent MG-ADL Improvement Independent of Region PBO-adjusted MG-ADL Δ: −1.25 East Asia vs −1.30 EU / Rest of World No. of Subjects at LS Mean Difference from Subgroup Treatment Arm Baseline (n) Placebo (95% CI) Region East Asia Placebo 24 -- Nipocalimab 24 -1.251 (-2.904,0.
Slide 55: Sjögren's: Ianalumab Shows Consistent Activity Independent of Region
Sjögren’s: Ianalumab Shows Consistent Activity Independent of Region No signal of reduced effect in Novartis NEPTUNUS China subgroup Ianalumab Telitacicept Global China Subgroup China Phase 3 300mg QM Placebo 300mg QM Placebo 160mg Placebo N=305 N=307 N=29 N=36 N=127 N=127 Mean Change from Baseline
Slide 56: SLE: Benlysta Shows Consistent SRI-4 Treatment Effect Despite Varying APAC Enrollment
SLE: Benlysta Shows Consistent SRI-4 Treatment Effect Despite Varying APAC Enrollment Across Multiple Phase 3 Trials SRI-4 Response Rates by Geography in Benlysta Pivotal Trials Overall Population 39% APAC Subgroup 0% APAC 100% APAC APAC: 39% Taiwan: 11 sites 78% US/Canada & W. 76.3% China 70% LatAm
Slide 57: IgAN: BAFF/APRIL Assets Show Consistent Activity Independent of Region
IgAN: BAFF/APRIL Assets Show Consistent Activity Independent of Region Objective endpoints, quantitative biomarkers, and limited placebo sensitivity concern Why IgAN Is The Benchmark PBO- Baseline Adjusted PBO UPCR Gd-IgA1 AEs Leading to Limited Placebo Sensitivity: UPCR reduction Agent Region UPCR
Slide 58: Significant Near-Term Expansion Opportunities
Significant Near-Term Expansion Opportunities >1M+ US diagnosed patients with Myasthenia Gravis, Sjögren's Disease, and other B-cell mediated autoimmune disease 380k US diagnosed patients with Myasthenia Gravis and Sjögren's Disease 90k US diagnosed patients with Myasthenia Gravis Beachhead Follow-O
Slide 59: Advancing The Leading BAFF/APRIL Inhibitor
2026: Advancing The Leading BAFF/APRIL Inhibitor 01 MYASTHENIA GRAVIS Enrollment Complete; Global Phase 3 Topline Data in 1H27 ~$515M Runway into Early 2029* 02 Best-in-Disease, Commercially Approved in China SJÖGREN’S DISEASE Global Phase 3 Initiated; FPD in 1Q26 Best-in-Disease, Commercially Appro
Slide 60: Thank You.
Thank You. LinkedIn.com/company/vor-bio Investors@vorbio.com Vorbio.com 60
Vor Biopharma — Investor Presentation (September 2026) on 6ix